NCT07626736 Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC
| NCT ID | NCT07626736 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wen-zhao ZHONG |
| Condition | Nonsmall Cell Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 300 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2027-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 300 participants in total. It began in 2025-12-01 with a primary completion date of 2027-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the effectiveness and safety of a locally deployed artificial intelligence (AI) decision-support model in the multidisciplinary team (MDT) process for patients with non-small cell lung cancer (NSCLC). The main questions it aims to answer : What is the level of agreement between treatment recommendations generated by the AI model and those made by a traditional MDT? How often do clinicians modify their final treatment decision after reviewing the AI model's recommendation? Researchers will compare treatment plans from the traditional MDT (Arm 1), the AI model (Arm 2), and the clinician's final decision after reviewing the AI output (Arm 3) to assess consistency, decision modification rates, and clinical efficiency. Participants will: Have their clinical, imaging, and molecular data submitted to both the traditional MDT and the AI model for independent treatment recommendations Receive a final treatment plan determined by clinicians after reviewing both recommendations, with follow-up for safety and survival outcomes
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years; 2. MDT (Multidisciplinary Team) discussion deems a systemic treatment plan necessary; 3. Complete clinical, imaging, and molecular pathological data. Exclusion Criteria: 1. Stage I patients; 2. Diagnosed with a thoracic tumor other than NSCLC; 3. Lack of detailed medical data, or missing data;
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07626736 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Nonsmall Cell Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07626736 currently recruiting?
Yes, NCT07626736 is actively recruiting participants. Contact the research team at liangtsing99@163.com for enrollment information.
Where is the NCT07626736 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07626736 clinical trial?
NCT07626736 is sponsored by Wen-zhao ZHONG. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.